- Investing Ideas
- Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
2
2 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
2 companies
Selvita
Market Cap: zł560.8m
Provides drug discovery, drug development, and contract testing services in Poland.
New
SLV
zł29.80
7D
-0.8%
1Y
-1.7%
Ryvu Therapeutics
Market Cap: zł330.2m
A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.
New
RVU
zł14.28
7D
-15.8%
1Y
-53.3%